The Latest
-
Marko Georgiev / Stringer via Getty Images
Q&AKeytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut
Long-term results showed five-year survival numbers for lung cancer patients that surpassed all others, and Merck's VP of oncology research tells us what he's excited about.
-
Sponsored by Avant Healthcare
The evolving roles and responsibilities of digital opinion leaders in medical education
In the past, patients entrusted their healthcare providers to provide information about health-related matters.
-
Stock via Getty Images
Q&AClinical trials haven’t harnessed the digital revolution — TransCelerate’s latest initiative aims to change that
The nonprofit’s VP of portfolio management discussed its “most transformative” digital initiative to date.
-
zennie via Getty Images
How do Biogen-Eisai’s two Alzheimer’s drugs stack up?
Biogen and Eisai's newest Alzheimer's success begs comparison to their past debacle — and bolsters the amyloid theory.
-
Stock via Getty Images
Q&ACompass has the most advanced psychedelic drug in trials — but it needs a new approach to rollout to make it a success
The company's CEO, Kabir Nath, discusses potential roadblocks to commecialization that await its psilocybin treatment for depression.
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Pepper Bio’s Samantha Dale Strasser
The co-founder of Pepper Bio entered the biotech world three years ago with the goal of transforming drug discovery through the emerging discipline of transomics.
-
Stock via Getty Images
Q&AWhy precision medicine could be the next frontier in treating autism
Swiss-based Stalicla is banking on an AI-driven precision medicine discovery platform to deliver needed therapies in the autism space.
-
NanoStockk via Getty Images
Q&AThat’s not Angry Birds — that’s your doctor learning about novel drugs through gaming
How pharma companies can teach physicians about mechanism of action and other medication lessons with interactive mobile games.
-
Illustration: Matthieu Bourel for Industry Dive
PharmaVoice 100The 2022 PharmaVoice 100
From standout executives to R&D pioneers — this year’s class of honorees is defining the next era of leadership.
-
Shaun Lucas/PharmaVoice
The 2022 Red Jacket honorees
Our annual PharmaVoice 100 “hall of fame” winners raise the bar on transformative leadership in life sciences.
-
Permission granted by Ben Yerxa
Profile // PharmaVoice 100Entrepreneurs: Ben Yerxa
The CEO in retinal diseases sees opportunities for drug development success by merging the work of a gene therapy startup with venture philanthropy.
-
Permission granted by John Oyler
Profile // PharmaVoice 100Entrepreneurs: John Oyler
The CEO of BeiGene is using innovative business strategies to help the oncology biotech quickly hit new heights.
-
Permission granted by Penelope Manasco
Profile // PharmaVoice 100Entrepreneurs: Dr. Penelope Manasco
How the NIH-trained scientist and CEO of MANA RBM is charting a new way forward in conducting clinical trials.
-
Permission granted by Bobak Azamian
Profile // PharmaVoice 100Entrepreneurs: Dr. Bobak Azamian
The CEO is bringing his vision for innovative eye therapies to Tarsus Pharmaceuticals.
-
Permission granted by WeiQing Zhou
Profile // PharmaVoice 100Entrepreneurs: WeiQing Zhou
The COO has launched two jewels in the biotech world that complement each other while serving broader innovation goals throughout the industry.
-
Permission granted by Jeanne Magram
Profile // PharmaVoice 100Innovators: Jeanne Magram
Celsius Therapeutics’ CSO is turning ideas into approved medicines for patients with cancer and autoimmune diseases.
-
Permission granted by Andrew Miller
Profile // PharmaVoice 100Entrepreneurs: Andrew Miller
The founder and COO of Karuna Therapeutics is leveraging a combination of persistence and adaptability to scale up the biopharmaceutical company.
-
Permission granted by Dr. Cristian Massacesi
Profile // PharmaVoice 100Innovators: Dr. Cristian Massacesi
With the goal of redefining how medicines are made, the CMO and oncology CDO is transforming AstraZeneca’s oncology development.
-
Permission granted by Jim Doherty
Profile // PharmaVoice 100Innovators: Jim Doherty
Sage Therapeutics’ chief development officer is leveraging innovative development strategies to create success against hard-to-treat brain disorders.
-
Permission granted by Dr. Judith Klimovsky
Profile // PharmaVoice 100Innovators: Dr. Judith Klimovsky
The executive vice president and chief business officer of Genmab is using decades of experience in oncology R&D to fuel advances in antibody-drug conjugates.
-
Permission granted by Barbara Klencke
Profile // PharmaVoice 100Innovators: Dr. Barbara Klencke
The chief medical officer at Sierra Oncology, a GSK company, is working to make high-impact changes for rare cancer patients.
-
Permission granted by Jennifer Kelly
Profile // PharmaVoice 100Tech Wizards: Jennifer Kelly
The president of patient experience is helping transform clinical trials with an innovative platform.
-
Permission granted by Kunal Ghosh
Profile // PharmaVoice 100Tech Wizards: Kunal Ghosh
The leader of Inscopix embodies a 'bootstrap' approach to entrepreneurship, from soldering early versions of the Inscopix technology to taking a 'science-first' approach to fundraising.
-
Permission granted by Houda Hachad
Profile // PharmaVoice 100Tech Wizards: Houda Hachad
This inventor and 'entrepreneurial scientist' is developing new technologies to manage data and use insights from genomic testing at AccessDx Laboratory.
-
Permission granted by Baba Shetty
Profile // PharmaVoice 100Tech Wizards: Baba Shetty
The pragmatic president of technology and data solutions at Syneos Health helps healthcare companies do what they imagine.
-
Permission granted by Nekzad Shroff
Profile // PharmaVoice 100Tech Wizards: Nekzad Shroff
Considered one of the industry’s ‘most powerful minds,’ the VP of product management at Saama is developing digital solutions with impact.
